<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01199887</url>
  </required_header>
  <id_info>
    <org_study_id>IW001-01</org_study_id>
    <nct_id>NCT01199887</nct_id>
  </id_info>
  <brief_title>Trial Of IW001 in Patients With Idiopathic Pulmonary Fibrosis</brief_title>
  <official_title>A Phase One, Open Label, Multi-Dose Study to Evaluate the Safety, Tolerability, and Biologic Effects of Three Doses of IW001 in Patients With Idiopathic Pulmonary Fibrosis (IPF)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ImmuneWorks</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ImmuneWorks</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open label, Phase One, multicenter study, designed to evaluate the safety,
      tolerability, to explore the biologic effects, and to explore the clinical effects of the
      following doses of IW001: 0.1mg/day, 0.5 mg/day, and 1.0 mg/day, when administered once a day
      orally for 24 weeks in patients with IPF.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      IW001 is a therapeutic designed to treat anti-Col (V)-mediated autoimmune diseases via oral
      tolerance. With the identification of the specific antigen involved in the autoimmune disease
      process in IPF, IW001 induced oral tolerance may be an effective treatment. IW001 is taken
      orally, introduced into the mucosal immune system at the Peyer's Patches in the distal small
      intestine, where antigen-presenting cells present the antigen to regulatory T cells (Tregs).
      These antigen-specific Tregs enter the blood stream and traffic to areas where the specific
      antigen has generated an autoimmune response. Thus, IW001 may produce selective suppression
      of immune responses against Col (V).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2010</start_date>
  <completion_date type="Actual">October 2012</completion_date>
  <primary_completion_date type="Actual">October 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the safety and tolerability of three doses of IW001 (0.1 mg/day, 0.5 mg/day, and 1.0 mg/day orally) in patients with IPF patients over a 24 week treatment period.</measure>
    <time_frame>Monthly during the 24 week treatment period.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To explore the biologic effects of IW001 on T-cell and B-cell reactivity. To explore relationships between Col V reactivity and clinical measures of lung function in patients with IPF.</measure>
    <time_frame>Monthly during the 24 week treatment period.</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Idiopathic Pulmonary Fibrosis</condition>
  <arm_group>
    <arm_group_label>IW001</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Three dose cohorts, 0.1 mg, 0.5 mg, 1.0 mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IW001</intervention_name>
    <description>IW001, 0.1 mg, 0.5 mg, 1.0 mg PO daily for 24 weeks.</description>
    <arm_group_label>IW001</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients must meet all of the following to be included in the study:

               1. Diagnosis of IPF (ATS criteria) prior to the Baseline visit.

               2. Forced Vital Capacity (FVC) ≥ 50% of predicted.

               3. Lung Diffusion Capacity (DLCO) ≥ 35% of predicted.

               4. Ages 35-75 years inclusive.

               5. Positive for anti-Col (V) antibodies.

               6. White blood cell count (WBC) ≥ 2500 mm3.

               7. Hematocrit ≥ 25% and ≤ 59%.

               8. Platelets ≥ 100,000 mm3.

               9. Creatinine ≤ 1.5x Upper Limits of Normal (ULN).

              10. Bilirubin ≤ 1.5x ULN.

              11. Aspartate aminotransferase (AST, SGOT) ≤ 1.5x ULN.

              12. Females of child-bearing potential (defined as less than one year post-menopausal
                  or not surgically sterile) must be using an acceptable method of birth control or
                  practicing abstinence from the time consent is signed until 30 days after
                  treatment discontinuation. If sexually active, female patients must use a double
                  barrier method of birth control, such as a condom and spermicidal. Patient must
                  have a negative pregnancy test at the Screening and Baseline visits.

              13. Willing and able to provide adequate written informed consent.

                  Exclusion Criteria:

          -  Patients will be excluded from the study for any of the following:

               1. Concurrent use of systemic corticosteroids or immunosuppressives within 30 days
                  of the Baseline visit.

               2. Chronic NSAID use (limited, i.e., up to 72 hours continuous use of NSAIDs will be
                  permitted during the study), (see Section 9, concomitant medications).

               3. N-acetyl cysteine (NAC) use within 14 days of the Baseline visit.

               4. Any disease, condition or surgery (e.g. inflammatory bowel disease, surgical
                  resection) that may cause malabsorption of IW001.

               5. Known or suspected allergy to bovine products.

               6. Concurrent or prior use of any experimental medication within 30 days of the
                  Baseline visit.

               7. History of smoking within three months prior to the Baseline visit.

               8. Known Hepatitis C or Human Immunodeficiency Virus (HIV) infections.

               9. Evidence of active infection at the Baseline visit.

              10. History of unstable or deteriorating cardiac disease.

              11. Myocardial infarction, coronary artery bypass, or angioplasty within 6 months of
                  the Baseline visit.

              12. Unstable angina pectoris or congestive heart failure requiring hospitalization
                  within 6 months of the Baseline visit.

              13. Uncontrolled arrhythmia.

              14. Patient has a history of illicit drug or alcohol abuse in the past year or
                  current evidence of such abuse or addiction in the opinion of the Investigator.

              15. Patient has positive findings on urine drug screen.

              16. Any other clinically significant illness, that, in the opinion of the
                  Investigator, might put the patient at risk of harm during the study or might
                  adversely affect the interpretation of the study data.

              17. Females who are pregnant and/or lactating.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Terrence Chew, MD</last_name>
    <role>Study Director</role>
    <affiliation>ImmuneWorks, Medical Consultant</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IUPUI</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Louisville</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Newark Beth Israel Hospital</name>
      <address>
        <city>Newark</city>
        <state>New Jersey</state>
        <zip>07112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43221</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Vermont</name>
      <address>
        <city>Burlington</city>
        <state>Vermont</state>
        <zip>05401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>American Thoracic Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS). Am J Respir Crit Care Med. 2000 Feb;161(2 Pt 1):646-64. Review.</citation>
    <PMID>10673212</PMID>
  </reference>
  <reference>
    <citation>Raghu G, Weycker D, Edelsberg J, Bradford WZ, Oster G. Incidence and prevalence of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2006 Oct 1;174(7):810-6. Epub 2006 Jun 29.</citation>
    <PMID>16809633</PMID>
  </reference>
  <reference>
    <citation>Martinez FJ, Safrin S, Weycker D, Starko KM, Bradford WZ, King TE Jr, Flaherty KR, Schwartz DA, Noble PW, Raghu G, Brown KK; IPF Study Group. The clinical course of patients with idiopathic pulmonary fibrosis. Ann Intern Med. 2005 Jun 21;142(12 Pt 1):963-7.</citation>
    <PMID>15968010</PMID>
  </reference>
  <reference>
    <citation>Walter N, Collard HR, King TE Jr. Current perspectives on the treatment of idiopathic pulmonary fibrosis. Proc Am Thorac Soc. 2006 Jun;3(4):330-8. Review.</citation>
    <PMID>16738197</PMID>
  </reference>
  <reference>
    <citation>Trulock EP, Edwards LB, Taylor DO, Boucek MM, Keck BM, Hertz MI. Registry of the International Society for Heart and Lung Transplantation: twenty-second official adult lung and heart-lung transplant report--2005. J Heart Lung Transplant. 2005 Aug;24(8):956-67.</citation>
    <PMID>16102428</PMID>
  </reference>
  <reference>
    <citation>Kim DS, Collard HR, King TE Jr. Classification and natural history of the idiopathic interstitial pneumonias. Proc Am Thorac Soc. 2006 Jun;3(4):285-92. Review.</citation>
    <PMID>16738191</PMID>
  </reference>
  <reference>
    <citation>Maher TM, Wells AU, Laurent GJ. Idiopathic pulmonary fibrosis: multiple causes and multiple mechanisms? Eur Respir J. 2007 Nov;30(5):835-9. Review.</citation>
    <PMID>17978154</PMID>
  </reference>
  <reference>
    <citation>Hunninghake GW, Schwarz MI. Does current knowledge explain the pathogenesis of idiopathic pulmonary fibrosis? A perspective. Proc Am Thorac Soc. 2007 Aug 15;4(5):449-52. Review.</citation>
    <PMID>17684287</PMID>
  </reference>
  <reference>
    <citation>Bobadilla JL, Love RB, Jankowska-Gan E, Xu Q, Haynes LD, Braun RK, Hayney MS, Munoz del Rio A, Meyer K, Greenspan DS, Torrealba J, Heidler KM, Cummings OW, Iwata T, Brand D, Presson R, Burlingham WJ, Wilkes DS. Th-17, monokines, collagen type V, and primary graft dysfunction in lung transplantation. Am J Respir Crit Care Med. 2008 Mar 15;177(6):660-8. doi: 10.1164/rccm.200612-1901OC. Epub 2008 Jan 3.</citation>
    <PMID>18174545</PMID>
  </reference>
  <reference>
    <citation>Burlingham WJ, Love RB, Jankowska-Gan E, Haynes LD, Xu Q, Bobadilla JL, Meyer KC, Hayney MS, Braun RK, Greenspan DS, Gopalakrishnan B, Cai J, Brand DD, Yoshida S, Cummings OW, Wilkes DS. IL-17-dependent cellular immunity to collagen type V predisposes to obliterative bronchiolitis in human lung transplants. J Clin Invest. 2007 Nov;117(11):3498-506.</citation>
    <PMID>17965778</PMID>
  </reference>
  <reference>
    <citation>Faria AM, Weiner HL. Oral tolerance. Immunol Rev. 2005 Aug;206:232-59. Review.</citation>
    <PMID>16048553</PMID>
  </reference>
  <reference>
    <citation>Whitacre CC, Song F, Wardrop RM 3rd, Campbell K, McClain M, Benson J, Guan Z, Gienapp I. Regulation of autoreactive T cell function by oral tolerance to self-antigens. Ann N Y Acad Sci. 2004 Dec;1029:172-9. Review.</citation>
    <PMID>15681756</PMID>
  </reference>
  <reference>
    <citation>Nussenblatt R. Orally and nasally induced tolerance studies in ocular inflammatory disease: guidance for future interventions. Ann N Y Acad Sci. 2004 Dec;1029:278-85. Review.</citation>
    <PMID>15681765</PMID>
  </reference>
  <reference>
    <citation>Artik S, Haarhuis K, Wu X, Begerow J, Gleichmann E. Tolerance to nickel: oral nickel administration induces a high frequency of anergic T cells with persistent suppressor activity. J Immunol. 2001 Dec 15;167(12):6794-803.</citation>
    <PMID>11739495</PMID>
  </reference>
  <reference>
    <citation>Barnett ML, Kremer JM, St Clair EW, Clegg DO, Furst D, Weisman M, Fletcher MJ, Chasan-Taber S, Finger E, Morales A, Le CH, Trentham DE. Treatment of rheumatoid arthritis with oral type II collagen. Results of a multicenter, double-blind, placebo-controlled trial. Arthritis Rheum. 1998 Feb;41(2):290-7. Erratum in: Arthritis Rheum 1998 May;41(5):938.</citation>
    <PMID>9485087</PMID>
  </reference>
  <reference>
    <citation>McKown KM, Carbone LD, Bustillo J, Seyer JM, Kang AH, Postlethwaite AE. Induction of immune tolerance to human type I collagen in patients with systemic sclerosis by oral administration of bovine type I collagen. Arthritis Rheum. 2000 May;43(5):1054-61.</citation>
    <PMID>10817559</PMID>
  </reference>
  <reference>
    <citation>Carbone LD, McKown K, Pugazhenthi M, Barrow KD, Warrington K, Somes G, Postlethwaite AE. Dosage effects of orally administered bovine type I collagen on immune function in patients with systemic sclerosis. Arthritis Rheum. 2004 Aug;50(8):2713-5.</citation>
    <PMID>15334493</PMID>
  </reference>
  <reference>
    <citation>Postlethwaite AE, Wong WK, Clements P, Chatterjee S, Fessler BJ, Kang AH, Korn J, Mayes M, Merkel PA, Molitor JA, Moreland L, Rothfield N, Simms RW, Smith EA, Spiera R, Steen V, Warrington K, White B, Wigley F, Furst DE. A multicenter, randomized, double-blind, placebo-controlled trial of oral type I collagen treatment in patients with diffuse cutaneous systemic sclerosis: I. oral type I collagen does not improve skin in all patients, but may improve skin in late-phase disease. Arthritis Rheum. 2008 Jun;58(6):1810-22. doi: 10.1002/art.23501.</citation>
    <PMID>18512816</PMID>
  </reference>
  <reference>
    <citation>Baccarani U, Adani GL, Montanaro D, Risaliti A, Lorenzin D, Avellini C, Tulissi P, Groppuzzo M, Currò G, Luvisetto F, Beltrami A, Bresadola V, Viale PL, Bresadola F. De novo malignancies after kidney and liver transplantations: experience on 582 consecutive cases. Transplant Proc. 2006 May;38(4):1135-7.</citation>
    <PMID>16757287</PMID>
  </reference>
  <reference>
    <citation>Yasufuku K, Heidler KM, O'Donnell PW, Smith GN Jr, Cummings OW, Foresman BH, Fujisawa T, Wilkes DS. Oral tolerance induction by type V collagen downregulates lung allograft rejection. Am J Respir Cell Mol Biol. 2001 Jul;25(1):26-34.</citation>
    <PMID>11472972</PMID>
  </reference>
  <reference>
    <citation>Mizobuchi T, Yasufuku K, Zheng Y, Haque MA, Heidler KM, Woods K, Smith GN Jr, Cummings OW, Fujisawa T, Blum JS, Wilkes DS. Differential expression of Smad7 transcripts identifies the CD4+CD45RChigh regulatory T cells that mediate type V collagen-induced tolerance to lung allografts. J Immunol. 2003 Aug 1;171(3):1140-7.</citation>
    <PMID>12874199</PMID>
  </reference>
  <verification_date>July 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 9, 2010</study_first_submitted>
  <study_first_submitted_qc>September 10, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 13, 2010</study_first_posted>
  <last_update_submitted>July 26, 2013</last_update_submitted>
  <last_update_submitted_qc>July 26, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 29, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>safety, biologic effects, IPF, autoimmune</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Pulmonary Fibrosis</mesh_term>
    <mesh_term>Idiopathic Pulmonary Fibrosis</mesh_term>
    <mesh_term>Idiopathic Interstitial Pneumonias</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

